Citadel Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $100M | Sell |
224,100
-24,300
| -10% | -$11.3M | 0.02% | 807 |
|
|
2025
Q4 | $113M | Sell |
248,400
-27,000
| -10% | -$11.6M | 0.02% | 779 |
|
|
2025
Q3 | $108M | Sell |
275,400
-43,400
| -14% | -$18.1M | 0.02% | 791 |
|
|
2025
Q2 | $142M | Buy |
318,800
+41,800
| +15% | +$19.3M | 0.02% | 551 |
|
|
2025
Q1 | $134M | Sell |
277,000
-70,100
| -20% | -$32.7M | 0.03% | 535 |
|
|
2024
Q4 | $140M | Buy |
347,100
+137,600
| +66% | +$63.8M | 0.02% | 557 |
|
|
2024
Q3 | $97.4M | Buy |
209,500
+74,100
| +55% | +$35.6M | 0.02% | 715 |
|
|
2024
Q2 | $63.5M | Sell |
135,400
-13,600
| -9% | -$5.9M | 0.01% | 969 |
|
|
2024
Q1 | $62.3M | Sell |
149,000
-38,500
| -21% | -$16.3M | 0.01% | 1039 |
|
|
2023
Q4 | $76.3M | Buy |
187,500
+46,700
| +33% | +$17.3M | 0.02% | 859 |
|
|
2023
Q3 | $49M | Buy |
140,800
+29,400
| +26% | +$10.3M | 0.01% | 1090 |
|
|
2023
Q2 | $39.2M | Sell |
111,400
-13,500
| -11% | -$4.55M | 0.01% | 1249 |
|
|
2023
Q1 | $39.4M | Sell |
124,900
-74,200
| -37% | -$22.3M | 0.01% | 1286 |
|
|
2022
Q4 | $57.5M | Sell |
199,100
-120,000
| -38% | -$36.6M | 0.01% | 1010 |
|
|
2022
Q3 | $92.4M | Sell |
319,100
-102,000
| -24% | -$29.3M | 0.02% | 646 |
|
|
2022
Q2 | $119M | Buy |
421,100
+149,100
| +55% | +$39.9M | 0.03% | 487 |
|
|
2022
Q1 | $71M | Sell |
272,000
-49,500
| -15% | -$11.7M | 0.01% | 855 |
|
|
2021
Q4 | $70.6M | Sell |
321,500
-26,600
| -8% | -$5.17M | 0.01% | 901 |
|
|
2021
Q3 | $63.1M | Sell |
348,100
-205,700
| -37% | -$40.2M | 0.01% | 956 |
|
|
2021
Q2 | $112M | Buy |
553,800
+339,200
| +158% | +$71M | 0.03% | 610 |
|
|
2021
Q1 | $46.1M | Buy |
214,600
+43,700
| +26% | +$9.6M | 0.01% | 1106 |
|
|
2020
Q4 | $40.4M | Buy |
170,900
+47,100
| +38% | +$10.8M | 0.01% | 1128 |
|
|
2020
Q3 | $33.7M | Sell |
123,800
-76,400
| -38% | -$21.1M | 0.01% | 1129 |
|
|
2020
Q2 | $58.1M | Sell |
200,200
-8,600
| -4% | -$2.33M | 0.02% | 709 |
|
|
2020
Q1 | $49.7M | Buy |
208,800
+32,000
| +18% | +$7.34M | 0.02% | 646 |
|
|
2019
Q4 | $38.7M | Buy |
176,800
+66,600
| +60% | +$13.5M | 0.02% | 944 |
|
|
2019
Q3 | $18.7M | Buy |
110,200
+8,600
| +8% | +$1.52M | 0.01% | 1534 |
|
|
2019
Q2 | $18.6M | Buy |
101,600
+21,200
| +26% | +$3.71M | 0.01% | 1483 |
|
|
2019
Q1 | $14.8M | Sell |
80,400
-19,500
| -20% | -$3.6M | 0.01% | 1622 |
|
|
2018
Q4 | $16.6M | Sell |
99,900
-36,700
| -27% | -$6.36M | 0.01% | 1389 |
|
|
2018
Q3 | $26.3M | Buy |
136,600
+54,300
| +66% | +$9.67M | 0.01% | 1177 |
|
|
2018
Q2 | $14M | Buy |
82,300
+33,600
| +69% | +$5.21M | 0.01% | 1621 |
|
|
2018
Q1 | $7.94M | Sell |
48,700
-24,200
| -33% | -$3.95M | ﹤0.01% | 1952 |
|
|
2017
Q4 | $10.9M | Sell |
72,900
-29,900
| -29% | -$4.43M | 0.01% | 1641 |
|
|
2017
Q3 | $15.6M | Buy |
102,800
+43,500
| +73% | +$6.55M | 0.01% | 1255 |
|
|
2017
Q2 | $7.64M | Sell |
59,300
-6,300
| -10% | -$758K | 0.01% | 1697 |
|
|
2017
Q1 | $7.17M | Buy |
65,600
+100
| +0.2% | +$8.8K | 0.01% | 1686 |
|
|
2016
Q4 | $4.83M | Buy |
65,500
+15,500
| +31% | +$1.26M | ﹤0.01% | 2042 |
|
|
2016
Q3 | $4.36M | Sell |
50,000
-700
| -1% | -$66.2K | ﹤0.01% | 2120 |
|
|
2016
Q2 | $4.36M | Sell |
50,700
-100
| -0.2% | -$8.64K | ﹤0.01% | 1937 |
|
|
2016
Q1 | $4.04M | Buy |
50,800
+7,800
| +18% | +$706K | 0.01% | 1960 |
|
|
2015
Q4 | $5.41M | Sell |
43,000
-16,700
| -28% | -$2.02M | 0.01% | 1744 |
|
|
2015
Q3 | $6.22M | Buy |
59,700
+12,100
| +25% | +$1.55M | 0.01% | 1722 |
|
|
2015
Q2 | $5.88M | Sell |
47,600
-800
| -2% | -$101K | 0.01% | 1905 |
|
|
2015
Q1 | $5.71M | Sell |
48,400
-57,700
| -54% | -$6.91M | 0.01% | 1898 |
|
|
2014
Q4 | $12.6M | Sell |
106,100
-5,300
| -5% | -$597K | 0.01% | 1236 |
|
|
2014
Q3 | $12.5M | Sell |
111,400
-38,400
| -26% | -$3.66M | 0.01% | 1213 |
|
|
2014
Q2 | $14.2M | Sell |
149,800
-12,200
| -8% | -$855K | 0.02% | 1024 |
|
|
2014
Q1 | $11.5M | Sell |
162,000
-1,600
| -1% | -$127K | 0.01% | 1173 |
|
|
2013
Q4 | $12.2M | Buy |
163,600
+49,400
| +43% | +$3.44M | 0.02% | 1091 |
|
|
2013
Q3 | $8.66M | Buy |
114,200
+37,700
| +49% | +$3M | 0.01% | 1193 |
|
|
2013
Q2 | $6.11M | Buy |
+76,500
| New | +$5.63M | 0.01% | 1389 |
|
Other funds holding VRTX
VCM
VPM
Citadel Advisors's VRTX Position: Q1 2026 in Review
Citadel Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 21% in Q1 2026, selling an estimated $40.9M and leaving 339,298 shares worth $152M. The position accounts for 0.02% of the portfolio, ranked #587.
Citadel Advisors first reported a position in VRTX in Q3 2013 and has held it in 49 quarters since. The position peaked at $369M in Q1 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Citadel Advisors held 339,298 shares of Vertex Pharmaceuticals worth $152M as of Q1 2026.
- Citadel Advisors sold 87,762 Vertex Pharmaceuticals shares in Q1 2026, an estimated $40.9M.
- Vertex Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #587 holding.
- Citadel Advisors first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 49 quarters since.
- Citadel Advisors's Vertex Pharmaceuticals position peaked at $369M in Q1 2021.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.